FIGURE 2 CALGB (Cancer and Leukemia Group B) 9221: Survival from landmark data according to crossover status (Kaplan–Meier method)
From the following article:
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Lewis R Silverman and Ghulam J Mufti
BACK TO ARTICLE
Figure 2. CALGB (Cancer and Leukemia Group B) 9221: Survival from landmark data according to crossover status (Kaplan–Meier method)
Patients with myelodysplastic syndrome were analyzed in three subgroups: those given supportive care who either never crossed over or crossed over after 6 months, those given supportive care who crossed over before 6 months, and those who were initially randomized to treatment with azacitidine. From Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429–2440. Reprinted with permission from the American Society of Clinical Oncology.
